1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pulmonary Drug Delivery Devices Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Pulmonary Drug Delivery Devices by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Pulmonary Drug Delivery Devices by Country/Region, 2018, 2022 & 2029
2.2 Pulmonary Drug Delivery Devices Segment by Type
2.2.1 Dry Powder Inhaler
2.2.2 Metered Dose Inhaler
2.2.3 Nebulizer
2.3 Pulmonary Drug Delivery Devices Sales by Type
2.3.1 Global Pulmonary Drug Delivery Devices Sales Market Share by Type (2018-2023)
2.3.2 Global Pulmonary Drug Delivery Devices Revenue and Market Share by Type (2018-2023)
2.3.3 Global Pulmonary Drug Delivery Devices Sale Price by Type (2018-2023)
2.4 Pulmonary Drug Delivery Devices Segment by Application
2.4.1 Asthma
2.4.2 COPD
2.4.3 Cystic Fibrosis
2.4.4 Other
2.5 Pulmonary Drug Delivery Devices Sales by Application
2.5.1 Global Pulmonary Drug Delivery Devices Sale Market Share by Application (2018-2023)
2.5.2 Global Pulmonary Drug Delivery Devices Revenue and Market Share by Application (2018-2023)
2.5.3 Global Pulmonary Drug Delivery Devices Sale Price by Application (2018-2023)
3 Global Pulmonary Drug Delivery Devices by Company
3.1 Global Pulmonary Drug Delivery Devices Breakdown Data by Company
3.1.1 Global Pulmonary Drug Delivery Devices Annual Sales by Company (2018-2023)
3.1.2 Global Pulmonary Drug Delivery Devices Sales Market Share by Company (2018-2023)
3.2 Global Pulmonary Drug Delivery Devices Annual Revenue by Company (2018-2023)
3.2.1 Global Pulmonary Drug Delivery Devices Revenue by Company (2018-2023)
3.2.2 Global Pulmonary Drug Delivery Devices Revenue Market Share by Company (2018-2023)
3.3 Global Pulmonary Drug Delivery Devices Sale Price by Company
3.4 Key Manufacturers Pulmonary Drug Delivery Devices Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Drug Delivery Devices Product Location Distribution
3.4.2 Players Pulmonary Drug Delivery Devices Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Pulmonary Drug Delivery Devices by Geographic Region
4.1 World Historic Pulmonary Drug Delivery Devices Market Size by Geographic Region (2018-2023)
4.1.1 Global Pulmonary Drug Delivery Devices Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Pulmonary Drug Delivery Devices Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Pulmonary Drug Delivery Devices Market Size by Country/Region (2018-2023)
4.2.1 Global Pulmonary Drug Delivery Devices Annual Sales by Country/Region (2018-2023)
4.2.2 Global Pulmonary Drug Delivery Devices Annual Revenue by Country/Region (2018-2023)
4.3 Americas Pulmonary Drug Delivery Devices Sales Growth
4.4 APAC Pulmonary Drug Delivery Devices Sales Growth
4.5 Europe Pulmonary Drug Delivery Devices Sales Growth
4.6 Middle East & Africa Pulmonary Drug Delivery Devices Sales Growth
5 Americas
5.1 Americas Pulmonary Drug Delivery Devices Sales by Country
5.1.1 Americas Pulmonary Drug Delivery Devices Sales by Country (2018-2023)
5.1.2 Americas Pulmonary Drug Delivery Devices Revenue by Country (2018-2023)
5.2 Americas Pulmonary Drug Delivery Devices Sales by Type
5.3 Americas Pulmonary Drug Delivery Devices Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Drug Delivery Devices Sales by Region
6.1.1 APAC Pulmonary Drug Delivery Devices Sales by Region (2018-2023)
6.1.2 APAC Pulmonary Drug Delivery Devices Revenue by Region (2018-2023)
6.2 APAC Pulmonary Drug Delivery Devices Sales by Type
6.3 APAC Pulmonary Drug Delivery Devices Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Pulmonary Drug Delivery Devices by Country
7.1.1 Europe Pulmonary Drug Delivery Devices Sales by Country (2018-2023)
7.1.2 Europe Pulmonary Drug Delivery Devices Revenue by Country (2018-2023)
7.2 Europe Pulmonary Drug Delivery Devices Sales by Type
7.3 Europe Pulmonary Drug Delivery Devices Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pulmonary Drug Delivery Devices by Country
8.1.1 Middle East & Africa Pulmonary Drug Delivery Devices Sales by Country (2018-2023)
8.1.2 Middle East & Africa Pulmonary Drug Delivery Devices Revenue by Country (2018-2023)
8.2 Middle East & Africa Pulmonary Drug Delivery Devices Sales by Type
8.3 Middle East & Africa Pulmonary Drug Delivery Devices Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Drug Delivery Devices
10.3 Manufacturing Process Analysis of Pulmonary Drug Delivery Devices
10.4 Industry Chain Structure of Pulmonary Drug Delivery Devices
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Drug Delivery Devices Distributors
11.3 Pulmonary Drug Delivery Devices Customer
12 World Forecast Review for Pulmonary Drug Delivery Devices by Geographic Region
12.1 Global Pulmonary Drug Delivery Devices Market Size Forecast by Region
12.1.1 Global Pulmonary Drug Delivery Devices Forecast by Region (2024-2029)
12.1.2 Global Pulmonary Drug Delivery Devices Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Pulmonary Drug Delivery Devices Forecast by Type
12.7 Global Pulmonary Drug Delivery Devices Forecast by Application
13 Key Players Analysis
13.1 Boehringer Ingelheim GmbH
13.1.1 Boehringer Ingelheim GmbH Company Information
13.1.2 Boehringer Ingelheim GmbH Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.1.3 Boehringer Ingelheim GmbH Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Boehringer Ingelheim GmbH Main Business Overview
13.1.5 Boehringer Ingelheim GmbH Latest Developments
13.2 Novartis AG
13.2.1 Novartis AG Company Information
13.2.2 Novartis AG Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.2.3 Novartis AG Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Novartis AG Main Business Overview
13.2.5 Novartis AG Latest Developments
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Information
13.3.2 GlaxoSmithKline Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.3.3 GlaxoSmithKline Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline Main Business Overview
13.3.5 GlaxoSmithKline Latest Developments
13.4 AstraZeneca
13.4.1 AstraZeneca Company Information
13.4.2 AstraZeneca Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.4.3 AstraZeneca Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 AstraZeneca Main Business Overview
13.4.5 AstraZeneca Latest Developments
13.5 Teva Pharmaceutical Industries
13.5.1 Teva Pharmaceutical Industries Company Information
13.5.2 Teva Pharmaceutical Industries Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.5.3 Teva Pharmaceutical Industries Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Teva Pharmaceutical Industries Main Business Overview
13.5.5 Teva Pharmaceutical Industries Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.6.3 Merck Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 MannKind
13.7.1 MannKind Company Information
13.7.2 MannKind Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.7.3 MannKind Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 MannKind Main Business Overview
13.7.5 MannKind Latest Developments
13.8 Bristol-Myers Squibb
13.8.1 Bristol-Myers Squibb Company Information
13.8.2 Bristol-Myers Squibb Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.8.3 Bristol-Myers Squibb Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bristol-Myers Squibb Main Business Overview
13.8.5 Bristol-Myers Squibb Latest Developments
13.9 Mylan N.V
13.9.1 Mylan N.V Company Information
13.9.2 Mylan N.V Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.9.3 Mylan N.V Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Mylan N.V Main Business Overview
13.9.5 Mylan N.V Latest Developments
13.10 Omron Corp
13.10.1 Omron Corp Company Information
13.10.2 Omron Corp Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.10.3 Omron Corp Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Omron Corp Main Business Overview
13.10.5 Omron Corp Latest Developments
13.11 F. Hoffmann-La Roche
13.11.1 F. Hoffmann-La Roche Company Information
13.11.2 F. Hoffmann-La Roche Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.11.3 F. Hoffmann-La Roche Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 F. Hoffmann-La Roche Main Business Overview
13.11.5 F. Hoffmann-La Roche Latest Developments
13.12 3M Healthcare
13.12.1 3M Healthcare Company Information
13.12.2 3M Healthcare Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.12.3 3M Healthcare Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 3M Healthcare Main Business Overview
13.12.5 3M Healthcare Latest Developments
13.13 Sunovion Pharmaceuticals
13.13.1 Sunovion Pharmaceuticals Company Information
13.13.2 Sunovion Pharmaceuticals Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.13.3 Sunovion Pharmaceuticals Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Sunovion Pharmaceuticals Main Business Overview
13.13.5 Sunovion Pharmaceuticals Latest Developments
13.14 Koninklijke Philips N.V
13.14.1 Koninklijke Philips N.V Company Information
13.14.2 Koninklijke Philips N.V Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.14.3 Koninklijke Philips N.V Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Koninklijke Philips N.V Main Business Overview
13.14.5 Koninklijke Philips N.V Latest Developments
13.15 Gerresheimer AG
13.15.1 Gerresheimer AG Company Information
13.15.2 Gerresheimer AG Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.15.3 Gerresheimer AG Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Gerresheimer AG Main Business Overview
13.15.5 Gerresheimer AG Latest Developments
13.16 Bespak
13.16.1 Bespak Company Information
13.16.2 Bespak Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.16.3 Bespak Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Bespak Main Business Overview
13.16.5 Bespak Latest Developments
13.17 AptarGroup
13.17.1 AptarGroup Company Information
13.17.2 AptarGroup Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.17.3 AptarGroup Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 AptarGroup Main Business Overview
13.17.5 AptarGroup Latest Developments
13.18 SHL Group
13.18.1 SHL Group Company Information
13.18.2 SHL Group Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.18.3 SHL Group Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 SHL Group Main Business Overview
13.18.5 SHL Group Latest Developments
13.19 Nypro Healthcare
13.19.1 Nypro Healthcare Company Information
13.19.2 Nypro Healthcare Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.19.3 Nypro Healthcare Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Nypro Healthcare Main Business Overview
13.19.5 Nypro Healthcare Latest Developments
13.20 Hovione
13.20.1 Hovione Company Information
13.20.2 Hovione Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.20.3 Hovione Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Hovione Main Business Overview
13.20.5 Hovione Latest Developments
13.21 Chiesi Farmaceutici S.P.A
13.21.1 Chiesi Farmaceutici S.P.A Company Information
13.21.2 Chiesi Farmaceutici S.P.A Pulmonary Drug Delivery Devices Product Portfolios and Specifications
13.21.3 Chiesi Farmaceutici S.P.A Pulmonary Drug Delivery Devices Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 Chiesi Farmaceutici S.P.A Main Business Overview
13.21.5 Chiesi Farmaceutici S.P.A Latest Developments
14 Research Findings and Conclusion
| ※参考情報 肺薬物送達装置は、吸入による薬物の投与を目的とした装置であり、主に肺や気道に直接薬物を届けるために設計されています。これらの装置は、特に呼吸器疾患の治療や管理において重要な役割を果たしています。例えば、喘息、慢性閉塞性肺疾患（COPD）、肺炎、肺結核などの疾患に対して有効な薬物送達手段として広く使用されています。 肺薬物送達装置の概念は、薬物の生物学的利用能を最大化することを目指しており、直接肺に送達されることで、全身における副作用を軽減し、迅速な薬理作用を実現します。これにより、患者は少量の薬で高い治療効果を得ることができるため、特に重要です。 まず、肺薬物送達装置の特徴について考えてみましょう。主な特徴の一つは、局所的な治療効果を得るための高い薬物濃度を肺に直接供給できる点です。これにより、全身的な副作用を減少させることができます。また、肺は非常に広い表面積を持ち、血液供給が豊富なため、吸収効率が高いのも特徴です。 肺薬物送達装置にはいくつかの種類があります。代表的な種類としては、メータードドーズインハラー（MDI）、ドライパウダーインハラー（DPI）、噴霧器（ネブライザー）があります。MDIは、圧縮されたガスと共に薬剤を噴出し、一定量を一回で投与する装置です。使い方は簡単ですが、患者がうまく吸入しないと効果が落ちることがあります。 DPIは、乾燥した粉末状態の薬剤を吸入する方式で、息を吸う力によって粉末が気道に送り込まれます。DPIは、エネルギー源が不要で、持ち運びも便利なため、患者の使用がしやすいという利点があります。 ネブライザーは、液体薬剤を霧状にして吸入させる装置で、特に重篤な呼吸器疾患や小児に使用されることが多いです。ネブライザーは、吸入が容易であるため、呼吸困難のある患者にも適していますが、使用には電源が必要な場合が多いという欠点もあります。 これらの装置は、薬物の種類や目的に応じて選択されます。例えば、喘息の急性発作時にはMDIが好まれることが多く、慢性的な肺機能障害にはDPIやネブライザーが利用されます。また、これらの装置は、薬物の理化学的特性や患者の年齢、運動能力に応じて最適なものを選ぶことが重要です。 ライフスタイルや健康状態に応じた適切な選択が、治療の成功に繋がります。肺薬物送達装置は、個別化医療の観点からも非常に重要であるといえます。 最近では、関連技術の進展もあり、より精密な薬物送達が可能になりつつあります。スマートインハラーや連携アプリなどのデジタル技術は、使用状況のモニタリングや投薬のタイミングを最適化するために利用されています。これにより、患者が自分の治療効果を把握し、適切な行動をとることがを助けることができます。 さらに、ナノテクノロジーの進展により、薬物の粒子サイズや形状を最適化し、肺への到達効率を向上させる試みも行われています。ナノ粒子を用いることで、薬物の放出速度や吸収率を調整できるため、より効果的な治療が期待されています。 肺薬物送達装置は、呼吸器系だけでなく、全身的な薬物治療にも役立つ可能性があります。例えば、特定の薬物が肺から全身循環に入ることで、他の治療法と組み合わせた新しい治療戦略が生まれることも考えられます。このように、肺薬物送達装置の研究と開発は、今後も進展が期待される分野です。 今後の課題としては、薬物の安定性や吸収率向上、患者の使用遵守の向上、ならびにコストの低減などがあります。これらをクリアすることで、さらに多くの患者にとって有用な治療法となることが期待されます。 総じて、肺薬物送達装置は、呼吸器疾患の治療において欠かせない要素であり、個別化医療の進展や新たな技術の導入により、今後ますます重要性が増すことでしょう。患者のQOL（生活の質）向上に寄与するため、多面的なアプローチが求められています。また、医療従事者はこれらの装置を適切に使用するための知識を持ち、患者教育を行うことも重要です。患者が自身の疾患や治療について正しく理解し、積極的に治療に参加することが、治療の成功に向けた重要な一歩となるでしょう。 |
